Supplementary Materials A. Patient post-COVID-19 condition self-assessment scale

Score <3

Persistent symptoms

Dependence for activities of daily living

Must lie or sit most of the

3<=Score <6

Persistent symptoms

Major limitation for activities of daily living

Frequent outbreaks of symptom manifestation

6<=Score<8

Partial decline of symptoms

Discomfort in carrying out daily activities and work

Less frequent outbreaks of symptom manifestation 8<=Score<10

Decline of most

Return to normal activities and work

Occasional symptoms in situations including physical or intellectual fatigue Score=10

Complete remission of COVId-19 persistent symptoms

Return to normal activities and work

Supplementary Materials B. Study symptom coding

Study symptom coding	Definition of symptoms group					
Smell and taste symptoms	Aguesia, anosmia					
Other ear-nose-throat symptoms	Tinnitus, vestibular involvement, odynophagia,rhinorrhea, dysphagia or other o torhinolaryngologic symptoms					
Asthenia	Asthenia or fatigue					
Fevers or Shivering	Fevers or shivering					
Cardiothoracic symptoms	Dyspnea, cough, thoracic pain and oppression, tachycardia, bradycardia or desaturation					
Neurological and neurocognitive symptoms						
Neurocognitive	Concentration and attention disorders (bradypsychia), immediate memory disorders, insomnia/hypersomnia					
Sensory disorders	Tingling, burning, neurogenic pain or balance disorders or paresthesia					
Other neurological	Difficulty swallowing, difficulty articulating, urinary retention, thermoregulation disorders, deafness, dysphonia, thermoregulation					
Psychic disorders	Anxiety, emotionality, thymic disorders, mood disorders					
Digestive symptoms	Diarrhea, abdominal pain, constipation, gastroparesis or vomiting/nausea					
Musculoskeletal	Myalgias, muscle weakness, arthralgias or tenosynovitis					
Cutaneous and vascular symptoms	Urticaria, eczema, subcutaneous hematoma or vascular inflammation					
Ophthalmic symptoms	Dry eyes, cloudy vision, conjunctivitis, orbit pain or visual blurring					

Supplementary Materials C: Detail of symptoms by class between initial long COVID phase ant one year follow-up

	Initial long COVID -19 phase					One year follow-up			
Symptoms		%	95%CI		N	%	95%	CI	
Smell and taste	82	35.5%	29.3%	-	42.0%	92	39.8%	33.5% -	46.5%
Ageusia	33	14.3%	10.0%	-	19.5%	63	27.3%	21.6%	33.5%
Anosmia	79	34.2%	28.1%	-	40.7%	80	34.6%	28.5% -	41.2%
Other ear-nose-throat	53	22.9%	17.7%	-	28.9%	146	63.2%	56.6% -	69.4%
Odynophagia or dysphagia	20	8.7%	5.4%	-	13.1%	61	26.4%	20.8%	32.6%
Tinnitus or vestibular involvement	37	16.0%	11.5%	-	21.4%	99	42.9%	36.4%	49.5%
Rhinorrhea		5.6%	3.0%	-	9.4%	54	23.4%	18.1% -	29.4%
Asthenia	178	77.1%	71.1%	-	82.3%	192	83.1%	77.7% -	87.7%
Fevers or Shivering	39	16.9%	12.3%	-	22.3%	75	32.5%	26.5%	38.9%
Cardiothoracic	187	81.0%	75.3%	-	85.8%	180	77.9%	72.0% -	83.1%
Cough	36	15.6%	11.2%	-	20.9%	54	23.4%	18.1%	29.4%
Thoracic pain, chest thightness and tachycardia	155	67.1%	60.6%	-	73.1%	117	50.6%	44.0%	57.3%
Dyspnea	132	57.1%	50.5%	-	63.6%	142	61.5%	54.9% -	67.8%
Other cardiothoracic	7	3.0%	1.2%	-	6.1%	38	16.5%	11.9% -	21.9%
Neurological and neurocognitive	193	83.5%	78.1%	-	88.1%	212	91.8%	87.5% -	95.0%
Neurocognitive	132	57.1%	50.5%	-	63.6%	174	75.3%	69.2%	80.7%
Sensory disorders	142	61.5%	54.9%	-	67.8%	190	82.3%	76.7%	87.0%
Other neurological	50	21.6%	16.5%	-	27.5%	91	39.4%	33.0% -	46.0%
Psychic	36	18.7%	13.4%	-	24.9%	158	68.4%	62.0%	74.3%
Digestive	93	40.3%	33.9%	-	46.9%	124	53.7%	47.0% -	60.2%
Diarrhea	56	24.2%	18.9%	-	30.3%	48	20.8%	15.7%	26.6%
Vomiting/Nausea	26	11.3%	7.5%	-	16.1%	47	20.3%	15.3%	26.1%
Other digestive	50	21.6%	16.5%	-	27.5%	104	45.0%	38.5% -	51.7%
Musculoskeletal	93	40.3%	33.9%	-	46.9%	182	78.8%	72.9% -	83.9%
Myalgias or muscle weakness	69	29.9%	24.0%	-	36.2%	122	52.8%	46.2%	59.4%
Arthralgias or tenosynovitis	51	22.1%	16.9%	-	28.0%	182	78.8%	72.9% -	83.9%
Cutaneous and vascular	72	31.2%	25.3%	-	37.6%	142	61.5%	54.9% -	67.8%
Urticaria or eczema Subcutaneous hematoma or vascular	32	13.9%	9.7%	-	19.0%	60	26.0%	20.4% -	32.1%
inflammation Other outeneous	44	19.0%	14.2%	_	24.7%	82	35.5%	29.3%	42.0%
Other cutaneous Ophthalmic	29	12.6%	8.6%	_	17.5%	90	39.0%	32.6% -	45.6%
Оришание	48	20.8%	15.7%	-	26.6%	103	44.6%	38.1% -	51.2%

Supplementary D: Cumulative percentage of participants reporting symptom remission at one year

